Bofanglutide Dosage, half-life & reference guide
Also known as GZR18 · Bofa
Reviewed Evidence: ModeratePublished by PepVault
A GLP-1 drug from Gan & Lee Pharmaceuticals designed for one shot every two weeks, with a long fatty-acid chain that makes it act gently and last. In its 52-week phase 3 trial in China, people lost about 15% (24 mg) and 18.5% (48 mg) of their weight, and a follow-on trial found that one shot a month then held the loss.
- Studied range
- 12–48 mgstarting dose 3 mg
- How often
- Every 2 weeks
- Half-life
- ~7 days
- Evidence
- ●●
●Moderate - Route
- SubQ injection
Studied in research — not a recommendation.
How it works.
GLP-1 receptor agonist, semaglutide's receptor, built from human GLP-1 with no unnatural amino acids and a long 22-carbon fatty-acid chain. The chain binds it tightly to albumin and slows its release from under the skin, so activity is gentler and longer: its half-life in people is about 7 days, and its trials give it once every two weeks. Developed by Gan & Lee Pharmaceuticals in China, in phase 3 there and phase 2 in the US.
Commonly reported: GI side effects during the step-ups, as with other GLP-1 drugs. It is not approved anywhere yet.
Half-life & active level
The half-life of Bofanglutide is ~7 days (measured in people: phase 1 in American and Chinese adults, Liu 2025).
Here's how a typical Bofanglutide schedule accumulates over four weeks (one-compartment estimate).
An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.
Your report
Taken Bofanglutide? What did you notice?
One tap to start. About 30 seconds, no account.

Model. Individual results vary.
Where Bofanglutide works.

Appetite & metabolism
In people. A GLP-1 drug from Gan & Lee Pharmaceuticals designed for one shot every two weeks, with a long fatty-acid chain that makes it act gently and last.
An area lights for what a peptide is used for and what people report, with the evidence beside it. It isn’t a promise that it works there.
Week by week.
What to expect in the first 8 weeks
- Onset
- Days–2 weeks
- Peak effect
- 52 weeks (phase 3 endpoint)
- Duration
- Ongoing
Day 1–28 · 3 mgRCT
Three milligrams, the first step
You're on 3 mg, where every group in the phase 2b trial began. Commonly reported: appetite dropping within days. In that trial, GI side effects came mostly in the early step-ups and eased over time.
The science
Phase 2b (Ji 2026; 340 Chinese adults): all groups started at 3 mg and escalated every 2–4 weeks (12 mg: 3-6-9-12; 24 mg: 3-6-9-12-18-24; 48 mg: 3-6-12-24-36-48). GI AEs "occurred predominantly during the early dose-escalation period and gradually decreased over time"; the 48 mg group, without the 9 and 18 mg steps, had the most, and the intermediate steps "substantially reduced the incidence of gastrointestinal AEs".
Sources- Ji et al. (phase 2b) (2026)
Updated Nov 2026
Day 29–210 · 12 mgRCT
Twelve milligrams every two weeks
You're at 12 mg, the lowest maintenance dose in the phase 2b trial. Given every two weeks, it took off about 10% of body weight by week 30, against about 1% on placebo.
The science
Phase 2b, week 30: 12 mg every 2 weeks −9.75% vs −1.15% on placebo (difference −8.60%); 18 mg −12.55% (difference −11.39%) (Ji 2026). Nausea 34.6% and vomiting 25.0% at 12 mg vs 9.1% and 12.1% on placebo.
Sources- Ji et al. (phase 2b) (2026)
Updated Nov 2026
Any dayRCT
What Bofanglutide is built on
Phase 1 trials in the US and China, a phase 1b/2a and a 30-week phase 2b in obesity, two phase 3 trials in China, and a US phase 2 against tirzepatide. It is not approved anywhere yet.
The science
Phase 1 (Liu 2025, Diabetes Obes Metab): half-life about 7 days in both American and Chinese adults, Tmax 60-96 h. Phase 1b/2a (Ji 2026, Cell Rep Med). Phase 2b (Ji 2026, Signal Transduct Target Ther; NCT06256562, sponsor Gan and Lee Pharmaceuticals). Phase 3: GRADUAL-1 (NCT06728124), GRADUAL-3, and a trial against semaglutide (Wegovy) (NCT07150975), plus sleep apnea trials; type 2 diabetes phase 3 (NCT06777238) completed.
Sources- Liu et al. (2025)
- Ji et al. (phase 1b/2a) (2026)
- Ji et al. (phase 2b) (2026)
Updated Nov 2026
With BPC-157Community
Why people add BPC-157 to a GLP-1
GI side effects come mostly with the step-ups, and BPC-157, first studied as a stomach-protecting peptide, is added to ease them. Commonly reported: smoother step-ups. No trial has tested the pair.
The science
BPC-157's early research was on gastric protection in animal studies (Sikiric 2018 review). No trial has tested it alongside bofanglutide or any GLP-1 drug; the pairing comes from community reports.
Sources- Sikiric et al. (2018)
Updated Nov 2026
After week 8
Day 57–364 · 24 mgRCT
Twenty-four milligrams, a phase 3 dose
You're at 24 mg, one of the two doses in the phase 3 trial. Every two weeks, it took off about 15% of body weight at 52 weeks, and more than 9 in 10 lost at least 5%.
The science
GRADUAL-1 (NCT06728124; 640 Chinese adults, baseline 93.7 kg): 24 mg every 2 weeks −15.12% vs −1.11% on placebo at week 52; 91.8% reached ≥5% (Gan & Lee, Jun-12-2026; topline). Phase 2b: 24 mg every 2 weeks −13.66% and 24 mg weekly −16.69% at week 30 (Ji 2026).
Sources- Gan & Lee (GRADUAL-1 release) (2026)
- Ji et al. (phase 2b) (2026)
Updated Nov 2026
Day 85–364 · 48 mgRCT
The top dose
You're at 48 mg, the highest dose tested. In the phase 3 trial it took off about 18.5% at 52 weeks. GI side effects were more common at this dose, especially with big steps on the way up.
The science
GRADUAL-1: 48 mg every 2 weeks −18.54% vs −1.11% at week 52; 98.1% reached ≥5% (Gan & Lee, Jun-12-2026). Phase 2b at 48 mg: −16.09% at week 30; nausea 64.1%, vomiting 62.5%, diarrhea 37.5%; completion 72% vs 85-92% in other groups (Ji 2026). US phase 2 (NCT06737042, 326 people): 48 mg −15.18% at 36 weeks with no plateau vs −16.93% on open-label tirzepatide 15 mg (Gan & Lee, Jun-12-2026).
Sources- Gan & Lee (GRADUAL-1 release) (2026)
- Ji et al. (phase 2b) (2026)
Updated Nov 2026
Day 365+RCT
One shot a month to hold it
After a year of shots every two weeks, Gan & Lee tested one shot a month. Over the next 24 weeks, weight held steady on the monthly dose, while those switched to placebo regained about 8.5%. Whether to continue, space out or stop is a call for you and your clinician.
The science
GRADUAL-3 (phase 3b): participants who completed 52 weeks of GRADUAL-1 were randomised by their last dose to bofanglutide 24 or 48 mg or placebo once monthly for 24 weeks: weight change +0.41% and −0.12% vs +8.52% on placebo (both p < 0.0001); mostly mild to moderate, transient GI events, no new safety signals (Gan & Lee, Nov-4-2026; topline).
Sources- Gan & Lee (GRADUAL-3 release) (2026)
Updated Nov 2026
Day 1 is the day you start it.
Phase 1 (Liu 2025, Diabetes Obes Metab), phase 2b (Ji 2026, Signal Transduct Target Ther; NCT06256562), Gan & Lee releases Jun-12-2026 (GRADUAL-1, US phase 2) and Nov-4-2026 (GRADUAL-3), registry records. Investigational.
Moderate evidence
Mixing and a typical run.
Example numbers
Reconstitution example
Reconstitute a 10 mg vial of Bofanglutide with 2 mL of bacteriostatic water and a 3 mg dose is 60 units on a U-100 syringe, about 3 doses per vial.
- Vial
- 10 mg
- Water
- 2 mL
- Amount
- 3 mg
Draw to60 units
1 mL insulin syringe · 100 units
Run notes
- Cycle
- Used continuously in its trials: every 2 weeks for 30 to 52 weeks, with steps every 2 to 4 weeks. In the GRADUAL-3 maintenance trial, people who had finished 52 weeks moved to one shot a month and held their weight for 24 weeks, while those switched to placebo regained about 8.5%.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- One SubQ shot every 2 weeks in its main trials (weekly in one phase 2b arm), from a GanleePen. The phase 2b started every group at 3 mg and stepped up every 2 to 4 weeks, through 6, 9, 12 and 18 mg to 24 mg, or in bigger jumps to 48 mg. After a year, one shot a month was tested to hold the loss. These are trial schedules, not an approved regimen.
- Route
- SubQ injection
- Stacks
- BPC-157 (GI support)
Safety.
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Decreased appetite
Interactions
No interaction results have been published; Gan & Lee has run studies of its effect on stomach emptying and on other drugs (NCT07128888) and on metformin (NCT06670209). GLP-1 drugs slow stomach emptying, which can change how oral medicines are absorbed. It is a GLP-1 drug itself, so it is not stacked with another one. With insulin or a sulfonylurea, discuss glucose monitoring with your clinician.
Safety notes
Bofanglutide has no label: it is still in trials. In the 30-week phase 2b trial, GI side effects (nausea, vomiting, diarrhea) affected 79% to 91% on bofanglutide vs 33% on placebo, mostly grade 1 to 2 and early in the step-ups; they were highest in the 48 mg group, which took bigger dose jumps, and adding in-between steps lowered them. In phase 3 the safety profile matched other GLP-1 drugs, with mostly mild to moderate, transient GI events and no new safety signals. It is a GLP-1 drug, so the class warnings in GLP-1 labels (including pancreatitis, gallbladder disease and the rodent thyroid C-cell finding) are the ones to read. These are trial findings to review with your clinician.
Goes with.
One question at a time.
Mixing charts by vial size.
Questions people ask.
What is Bofanglutide?
A GLP-1 drug from Gan & Lee Pharmaceuticals designed for one shot every two weeks, with a long fatty-acid chain that makes it act gently and last. In its 52-week phase 3 trial in China, people lost about 15% (24 mg) and 18.5% (48 mg) of their weight, and a follow-on trial found that one shot a month then held the loss.
How is Bofanglutide dosed in research?
The research range for Bofanglutide is 12–48 mg, every 2 weeks (or weekly), with a 3 mg starting dose. Studied in research — not a recommendation.
How long does Bofanglutide last?
The half-life of Bofanglutide is ~7 days (measured in people: phase 1 in American and Chinese adults, Liu 2025).
What do people report on Bofanglutide?
Commonly reported on Bofanglutide: GI side effects during the step-ups, as with other GLP-1 drugs. It is not approved anywhere yet.
Is Bofanglutide safe?
The research basis for Bofanglutide is moderate: animal studies + some human data. Common side effects in the library: nausea, vomiting, diarrhea and decreased appetite.
What does Bofanglutide stack with?
Common stacks for Bofanglutide: BPC-157 (GI support).
Research.
Reference.
- Cadence
Every 2 weeks
Every 2 weeks (or weekly)
- Half-life
~7 days
~7 days (measured in people: phase 1 in American and Chinese adults, Liu 2025)
- Research basis
●●
●ModerateAnimal studies + some human data
Reviewed How we check the library


